Lu Yang

5.1k citations

89 papers · 3.7k indexed · 2 hit papers · h-index 32

Impact in

Cancer Research top 0.5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Molecular Biology top 2%
- Circular RNAs in diseases
- RNA modifications and cancer
- Epigenetics and DNA Methylation

Papers in ⓘ

Molecular Biology 47
- Circular RNAs in diseases 13
- RNA modifications and cancer 8
Cancer Research 41
- Cancer-related molecular mechanisms research 20
- MicroRNA in disease regulation 17
- Breast Cancer Treatment Studies 5
- Cancer, Lipids, and Metabolism 4

Co-authors: Hailin Tang (26 shared papers)Xiaoming Xie (26 shared papers)Yanan Kong (13 shared papers)Xinhua Xie (14 shared papers)Xiaojia Huang (11 shared papers)Jin Wang (3 shared papers)Weidong Wei (9 shared papers)Michael M. Shen (1 shared paper)
Journals: PLoS ONE (6 papers)Cancer Letters (5 papers)Cell Death and Disease (3 papers)Frontiers in Oncology (3 papers)Frontiers in Cell and Developmental Biology (2 papers)
Partner nations: China United States Hong Kong

In The Last Decade

Lu Yang

84 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer 2022 · 167 citations

Peers

Countries citing papers authored by Lu Yang

Since Specialization

Citations

This map shows the geographic impact of Lu Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Yang more than expected).

Fields of papers citing papers by Lu Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Yang. The network helps show where Lu Yang may publish in the future.

Co-authors

The 25 scholars most cited alongside Lu Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lu Yang Line = papers co-authored together Lu Yang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 89 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Class I histone deacetylases (HDAC1–3) are histone lysine delactylases Science Advances ·Carlos Moreno–Yruela, Di Zhang, Wei Wei, Michael Bæk, Wenchao Liu, Jinjun Gao, Daniela Danková, Alexander L. Nielsen, Julie E. Bolding, Lu Yang, Samuel T. Jameson, Jiemin Wong, Christian A. Olsen, Yingming Zhao Hit paper breakdown →	2022	425
2	Essential role for p38α mitogen-activated protein kinase in placental angiogenesis Proceedings of the National Academy of Sciences ·John S. Mudgett, Jixiang Ding, Lucia Guh-Siesel, Nicole Chartrain, Lu Yang, Shobhna Gopal, Michael M. Shen	2000	323
3	circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression Theranostics ·Bo Chen, Weidong Wei, Xiaojia Huang, Xinhua Xie, Yanan Kong, Danian Dai, Lu Yang, Jin Wang, Hailin Tang, Xiaoming Xie	2018	212
4	Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition Science Translational Medicine ·Lu Yang, Youyou Zhang, Weiwei Shan, Zhongyi Hu, Jiao Yuan, Jingjiang Pi, Yueying Wang, Lingling Fan, Zhaoqing Tang, Chunsheng Li, Xiaowen Hu, János L. Tanyi, Yi Fan, Qihong Huang, Kathleen T. Montone, Chi V. Dang, Lin Zhang	2017	181
5	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer Nature Communications ·Yutian Zou, Shaoquan Zheng, Xinhua Xie, Feng Ye, Xiaoqian Hu, Zhi Tian, Shumei Yan, Lu Yang, Yanan Kong, Yuhui Tang, W. H. Tian, Jindong Xie, Xinpei Deng, Yan Zeng, Zhe‐Sheng Chen, Hailin Tang, Xiaoming Xie Hit paper breakdown →	2022	167
6	circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer Molecular Cancer ·Hailin Tang, Xiaojia Huang, Jin Wang, Lu Yang, Yanan Kong, Guanfeng Gao, Lijuan Zhang, Zhe‐Sheng Chen, Xiaoming Xie	2019	165
7	LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells Through Activation of Wnt/β-Catenin Signaling Stem Cells ·Lu Yang, Hailin Tang, Yanan Kong, Xinhua Xie, Jianping Chen, Cailu Song, Xiaoping Liu, Feng Ye, Ning Li, Neng Wang, Xiaoming Xie	2015	134
8	The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin Molecular Cancer ·Zehao Wang, Lu Yang, Peng Wu, Xing Li, Yuhui Tang, Xueqi Ou, Yue Zhang, Xiangsheng Xiao, Jin Wang, Hailin Tang	2022	118
9	Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22 Cancer Letters ·Hailin Tang, Yanan Kong, Jiaoli Guo, Yi Tang, Xinhua Xie, Lu Yang, Qi Su, Xiaoming Xie	2013	102
10	miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer Molecular Cancer Therapeutics ·Hailin Tang, Peng Liu, Lu Yang, Xinhua Xie, Ye Feng, Minqing Wu, Xiaoping Liu, Bo Chen, Lijuan Zhang, Xiaoming Xie	2014	101
11	Histone crotonylation promotes mesoendodermal commitment of human embryonic stem cells Cell stem cell ·Yi Fang, Xiaojiang Xu, Jun Ding, Lu Yang, Mary T. Doan, Peer W. F. Karmaus, Nathaniel W. Snyder, Yingming Zhao, Jian‐Liang Li, Xiaoling Li	2021	101
12	Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a Molecular and Cellular Biochemistry ·Jiaoli Guo, Wenping Li, Hongliu Shi, Xinhua Xie, Laisheng Li, Hailin Tang, Minqing Wu, Yanan Kong, Lu Yang, Jie Gao, Peng Liu, Weidong Wei, Xiaoming Xie	2013	94
13	miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer Cancer Letters ·Peng Liu, Hailin Tang, Bo Chen, Zhimin He, Min Deng, Minqing Wu, Xiaoping Liu, Lu Yang, Feng Ye, Xiaoming Xie	2014	90
14	Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer Journal of Hematology & Oncology ·Shaoquan Zheng, Lu Yang, Yutian Zou, Jie‐Ying Liang, Peng Liu, Guanfeng Gao, Anli Yang, Hailin Tang, Xiaoming Xie	2020	88
15	Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: A systematic review and meta-analysis of 13,110 patients International Immunopharmacology ·Hang Xu, Xiaonan Zheng, Jianzhong Ai, Lu Yang	2022	86
16	miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer Cancer Letters ·Bo Chen, Hailin Tang, Xiaoping Liu, Peng Liu, Lu Yang, Xinhua Xie, Feng Ye, Cailu Song, Xiaoming Xie, Weidong Wei	2014	83
17	miR-200c inhibits breast cancer proliferation by targeting KRAS Oncotarget ·Cailu Song, Longzhong Liu, Xiao-Qing Pei, Xiaoping Liu, Lu Yang, Feng Ye, Xinhua Xie, Jianping Chen, Hailin Tang, Xiaoming Xie	2015	80
18	CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression Epigenomics ·Yanan Kong, Lu Yang, Weidong Wei, Ning Lyu, Yutian Zou, Guanfeng Gao, Xueqi Ou, Xiaoming Xie, Hailin Tang	2019	72
19	MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer Oncotarget ·Xiaoping Liu, Hailin Tang, Jianping Chen, Cailu Song, Lu Yang, Peng Liu, Neng Wang, Xinhua Xie, Xiaoti Lin, Xiaoming Xie	2015	68
20	Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a Oncogene ·Xiaojia Huang, Xinhua Xie, Peng Liu, Lu Yang, Bo Chen, Cailu Song, Hailin Tang, Xiaoming Xie	2018	58

About Lu Yang

Lu Yang is a scholar working on Molecular Biology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 89 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (20 papers), MicroRNA in disease regulation (17 papers), Circular RNAs in diseases (13 papers), RNA modifications and cancer (8 papers), Cancer Cells and Metastasis (5 papers), Breast Cancer Treatment Studies (5 papers), Cancer Risks and Factors (5 papers) and Cancer, Lipids, and Metabolism (4 papers). The work is most often cited by research in Cancer Research (1.7k citations), Molecular Biology (2.7k citations), Oncology (777 citations), Immunology (273 citations) and Pulmonary and Respiratory Medicine (364 citations). Lu Yang has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Hailin Tang, Xiaoming Xie, Yanan Kong, Xinhua Xie, Xiaojia Huang, Jin Wang, Weidong Wei, Michael M. Shen, Jixiang Ding and Cailu Song. Their work appears in journals such as PLoS ONE, Cancer Letters, Cell Death and Disease, Frontiers in Oncology and Frontiers in Cell and Developmental Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact